

IN THE CLAIMS:

✓
Please add new claims 37 through 50 to the present application. All claims pending in the application are provided below.

Claim 19 (Previously Amended): A dosage form comprising:
a core comprising a drug formulation;
an interior membrane formed around the core, the interior membrane comprising 35 wt% to 70 wt% of a polymer possessing a lipophilic-attracting property, 25 wt% to 65 wt% of a flux enhancer, and 0 wt% to 10 wt% of a surfactant; and
an exterior membrane formed around the interior membrane, the exterior membrane comprising 35 wt% to 70 wt% of a polymer permeable to the passage of an aqueous fluid, 10 wt% to 40 wt% of a plasticizer, 20 wt% to 35 wt% of a peptide, and 0 wt% to 10 wt% of a surfactant.

Claim 20 (Previously Amended): The dosage form of claim 19, wherein the interior membrane contacts the exterior membrane, and an exit is present in the interior and exterior membranes for delivering the drug from the dosage form.

Claim 37 (New): A sustained release dosage form comprising:
a core formulation comprising a drug and an expandable composition; and
a bilayer membrane formed around the core formulation, the bilayer membrane comprising:

an interior lipophilic membrane comprising a lipid attracting membrane forming material and a flux enhancer, the interior membrane being formulated to soften and disintegrate as the interior membrane absorbs lipids from an environment of use; and

an exterior hydrophilic membrane comprising a semipermeable material and a compound possessing at least one peptide moiety, the exterior membrane being formulated and configured to delay disintegration of the interior membrane and lose mechanical integrity as the sustained release dosage form operates in the environment of use.

Claim 38 (New): The sustained release dosage form of claim 37, wherein the exterior hydrophilic membrane comprises:

20 wt % to 35 wt% of the compound possessing at least one peptide moiety;
35 wt% to 70 wt% of the semipermeable material;
10 wt% to 40 wt% of a plasticizer; and
0 wt% to 10 wt% of a surfactant.

Claim 39 (New): The sustained release dosage form of claim 37, wherein the hydrophilic

exterior membrane comprises:

20 wt% to 35 wt% of the compound possessing at least one peptide moiety;

35 wt% to 70 wt% of a member selected from the group consisting of a cellulose acylate, cellulose diacylate, and a cellulose triacylate polymer;

10 wt% to 40 wt% of a plasticizer that increases the aqueous diffusion coefficient of the exterior hydrophilic membrane and is selected from the group consisting of glycerin, triacetin, adipic acid, azelaic acid, citric acid, triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, butyryl trihexyl citrate, polyethylene glycol, diethylene glycol dipelargonate and triethylene glycol di(2-ethylbutrate); and

0 wt% to 10 wt% of a surfactant.

Claim 40 (New): The sustained release dosage form of claim 37, wherein the compound possessing at least one peptide moiety comprises 20 wt% to 35 wt% of the exterior membrane and comprises a protein possessing a molecular weight of 1500 to 350,000.

Claim 41 (New): The sustained release dosage form of claim 38, wherein the surfactant is selected from the group consisting of an anionic, amphoteric, cationic and nonionic surfactant.

Claim 42 (New): The sustained release dosage form of claim 37, wherein the compound possessing at least one peptide moiety comprises a member selected from the group consisting of reticulin, silk, keratin, casein, lactoglobulin, prolamine, gluten, albumin, elastin, soy protein, globulin, gelatin, collagen, and zein.

Claim 43 (New): The sustained release dosage form of claim 40, wherein the protein is sized between about 0.1 microns to 50 microns in one dimension.

Claim 44 (New): The sustained release dosage form of claim 37, wherein the interior lipophilic membrane comprises:

35 wt% to 70 wt% of the lipid attracting, membrane forming material;
25 wt% to 65 wt% of the flux enhancer; and
0 wt% to 10 wt% of a surfactant.

Claim 45 (New): The sustained release dosage form of claim 44, wherein the lipid attracting, membrane forming material includes a lipophilic polymer comprising poly(ethyl cellulose).

Claim 46 (New): The sustained release dosage form of claim 44, wherein the flux enhancer comprises hydroxyalkylcellulose, wherein the alkyl group comprises 1 to 6 carbon atoms.

Claim 47 (New): The sustained release dosage form of claim 44, wherein the lipophilic polymer comprises poly(ethyl cellulose) exhibiting a viscosity of 3 to 350 centipoise.

Claim 48 (New): The sustained release dosage form of claim 44, wherein the flux enhancer comprises a hydroxyalkylcellulose selected from the group consisting of hydroxyethylcellulose and hydroxypropylcellulose.

Claim 49 (New): The sustained release dosage form of claim 44, wherein the surfactant comprises a member selected from the group consisting of polyoxyl 4 stearate, polyoxyl 8 stearate, polyoxyl 20 stearate, polyoxyl 30 stearate, polyoxyl 40 stearate, polyoxyl 50 stearate, polyoxyl 100 stearate, polyoxyl 4 distearate and polyoxyl 150 distearate, and wherein the number refers to the surfactant polymer length in oxyethylene units.

D
Cont.

Claim 50 (New): The sustained release dosage form of claim 37, further comprising an exit through the bilayer membrane for delivering the drug from the dosage form.
